http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#Head http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#assertion http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#provenance http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#pubinfo http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#assertion http://purl.obolibrary.org/obo/DOID_11476 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_11476 http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB06643 http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association http://www.w3.org/2000/01/rdf-schema#label prolia is a rank ligand rankl inhibitor indicated for treatment of postmenopausal women with osteoporosis at high risk for fracture 1 1 treatment to increase bone mass in men with osteoporosis at high risk for fracture 1 2 treatment of glucocorticoid induced osteoporosis in men and women at high risk for fracture 1 3 treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer 1 4 treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer 1 5 prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture or multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy in postmenopausal women with osteoporosis prolia reduces the incidence of vertebral nonvertebral and hip fractures see clinical studies 14 1 prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture or multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy see clinical studies 14 2 prolia is indicated for the treatment of glucocorticoid induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7 5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months high risk of fracture is defined as a history of osteoporotic fracture multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy see clinical studies 14 3 prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer in these patients prolia also reduced the incidence of vertebral fractures see clinical studies 14 4 prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer see clinical studies 14 5 http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB06643 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#provenance http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#pubinfo http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#sig http://purl.org/nanopub/x/hasSignature PESP4v3M9hvId4z2935Yb2LtKm43QdCqtQhnguNgyvecR5+PvWzuODiWQ+h5JmAkdmLiPHCxT1qk3DCj3WbuMghW1rTRj1FUKS4If5OjYVDz8NwhVAG28IQ9tuc53pY1bLCvN93LW9w5cJL+20HORXjUHJzQJPJdPqNyifutUSM= http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4 http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4 http://purl.org/dc/terms/created 2021-07-03T14:58:51.850+02:00 http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAZ3PWgBVf_-K7EIz8UePDH5EPECOy5ulcIksTFc67pK4 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs